ReviewJournal of the International AIDS Society2011
New insights into HIV-1-primary skin disorders.
Review in Journal of the International AIDS Society, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 154 citations in OpenAlex.
- A novel community health worker tool outperforms WHO clinical staging for assessment of antiretroviral therapy eligibility in a resource-limited setting.Journal of acquired immune deficiency syndromes (1999) · 2014Trial
- Expansion of pathogens and restoration of human skin microbiome in CD4 T-cell lymphopenia.The Journal of investigative dermatology · 2026Article
- Immunomodulatory Therapy in Patients Living With HIV and Inflammatory Dermatoses: A Comprehensive Review of Current Protocols and Emerging Evidence.The Journal of clinical and aesthetic dermatology · 2026Article
- The dual roles of T cells and keratinocytes in seborrheic dermatitis: a narrative review.European journal of medical research · 2025Review
- Assessment of dermatological life quality in patients with cutaneous diseases at Universitas Academic Hospital.Journal of the colleges of medicine of South Africa · 2025Article
- Vitiligo: are microbes to blame?Bioscience of microbiota, food and health · 2025Review
- HIV-Associated Immune Dysregulation in the Skin: A Crucible for Exaggerated Inflammation and Hypersensitivity.The Journal of investigative dermatology · 2023Review
- Urticaria and HIV Infection: A Case Report.Cureus · 2022Article
- Therapeutic challenges of psoriasis in the HIV-infected patient: A case report.Experimental and therapeutic medicine · 2022Article
- An Overview of the Diagnosis and Management of Seborrheic Dermatitis.Clinical, cosmetic and investigational dermatology · 2022Review
- Antipruritic Effect of Nalbuphine, a Kappa Opioid Receptor Agonist, in Mice: A Pan Antipruritic.Molecules (Basel, Switzerland) · 2021Article
- Dermatological Opportunistic Infections in HIV Seropositive Patients: An Observational Study.Cureus · 2021Article
- Perspectives on skin disorder diagnosis among people living with HIV in southeastern Romania.Experimental and therapeutic medicine · 2021Article
- The prevalence and spectrum of mucocutaneous disease in South African people living with HIV and accessing care at a district-level hospital.Southern African journal of HIV medicine · 2020Article
- Mucocutaneous Manifestations in HIV-Infected Patients and Their Relationship to CD4 Lymphocyte Counts.Scientifica · 2020Article
- Skin Disease in Korean Human Immunodeficiency Virus Patient.Annals of dermatology · 2019Article
- Applications of SNAP-tag technology in skin cancer therapy.Health science reports · 2019Review
- Pathogenic Viruses Commonly Present in the Oral Cavity and Relevant Antiviral Compounds Derived from Natural Products.Medicines (Basel, Switzerland) · 2018Review
- Erythrodermic psoriasis and human immunodeficiency virus: association and therapeutic challenges.Anais brasileiros de dermatologia · 2018Article
- Pityriasis rosea in a patient with retrovirus infection and a history of syphilis and positive results of infection with hepatitis A virus, hepatitis B virus and hepatitis C virus.Postepy dermatologii i alergologii · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 3 countries.
Funding
Abstract
Since the first reports of AIDS, skin involvement has become a burdensome stigma for seropositive patients and a challenging task for dermatologist and infectious disease specialists due to the severe and recalcitrant nature of the conditions. Dermatologic manifestations in AIDS patients act as markers of disease progression, a fact that enhances the importance of understanding their pathogenesis.Broadly, cutaneous disorders associated with HIV type-1 infection can be classified as primary and secondary. While the pathogenesis of secondary complications, such as opportunistic infections and skin tumours, is directly correlated with a decline in the CD4+ T cell count, the origin of the certain manifestations primarily associated with the retroviral infection itself still remains under investigation.The focus of this review is to highlight the immunological phenomena that occur in the skin of HIV-1-seropositive patients, which ultimately lead to skin disorders, such as seborrhoeic dermatitis, atopic dermatitis, psoriasis and eosinophilic folliculitis. Furthermore, we compile the latest data on how shifts in the cytokines milieu, impairments of the innate immune compartment, reactions to xenobiotics and autoimmunity are causative agents in HIV-1-driven skin diseases. Additionally, we provide a thorough analysis of the small animal models currently used to study HIV-1-associated skin complications, centering on transgenic rodent models, which unfortunately, have not been able to fully unveil the role of HIV-1 genes in the pathogenesis of their primarily associated dermatological manifestations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.